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Summary Expression or introduction of the neuropeptide substance-P (SP; encoded by the
TAC1 gene in humans and Tac1 in rodents) in the amygdala induces anxiety related behaviour in
rodents. In addition, pharmacological antagonism of the main receptor of SP in humans; NK1, is
anxiolytic. In the current study, we show that the Tac1 locus is up-regulated in primary rat
amygdala neurones in response to activation of the glucocorticoid receptor (GR); a classic
component of the stress response. Using a combination of bioinformatics, electrophoretic
mobility shift assays (EMSA) and reporter plasmid magnetofection into rat primary amygdala
neurones we identified a highly conserved GR response sequence (2GR) in the human TAC1
promoter that binds GR in response to dexamethasone (Dex) or forskolin. We also identified a
second GR binding site in the human promoter that was polymorphic and whose T-allele is only
found in Japanese and Chinese populations. We present evidence that the T-allele of SNPGR
increases the activity of the TAC1 promoter through de-sequestration or de-repression of 2GR.
The identification of Dex/forskolin response elements in the TAC1 promoter in amygdala neurones
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suggests a possible link in the chain of molecular events connecting GR activation and anxiety. In
addition, the discovery of a SNP which can alter this response may have implications for our
understanding of the role of regulatory variation in susceptibility to stress in specific populations.
# 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).
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It is now evident that susceptibility to many forms of human
disease is caused by polymorphic variation in the regulatory
elements controlling the expression of genes rather than by
variation within the coding regions of these genes (Maurano
et al., 2012). However, the effects of polymorphic variation
on the activity of gene regulatory elements, or their
responses to activated signal transduction pathways, has
not been widely explored and remains poorly understood.
Substance P (SP), a neuropeptide that, along with the less
well characterised neurokinin-A (NKA), is encoded by the
human TAC1 gene (Tac1 in rodents) and is expressed in both
the medial and central amygdala where it modulates anxiety
levels (Ebner et al., 2008; Singewald et al., 2008; Zhao et al.,
2009). Stressful stimuli increase levels of SP and Tac1 mRNA
within the amygdala regions of restrained rodents (Ebner
et al., 2004; Sergeyev et al., 2005) an observation reminis-
cent of patients diagnosed with stress disorders (Geracioti
et al., 2006) or those placed in anxiety inducing situations
who have elevated levels of SP in their cerebral spinal fluid
(Michelgard et al., 2007). An interesting clue as to the
mechanism linking the stress response and the regulation
of SP comes from studies that demonstrate co-localisation of
the stress activated glucocorticoid receptor (GR) and Tac1
within cells of the central amygdala (Honkaniemi et al.,
1992). Interestingly, previous studies on adrenalectomised
rats demonstrated a significant up-regulation in Tac1 gene
expression in the amygdala of animals treated with corticos-
terone (Pompei et al., 1995). Glucocorticoids influence gene
expression within the brain by acting as ligands to the GR and
mineralocorticoid receptors (MR) that subsequently bind DNA
to modulate gene expression (Arnett et al., 2010). GR is
expressed in the central amygdala but has also been reported
in lateral amygdala (Johnson et al., 2005; Prager et al., 2011;
Reul and de Kloet, 1985). In addition, selective deletion of GR
in the central amygdala has been used to demonstrate its
critical role in the formation and consolidation of fear mem-
ory (Kolber and Muglia, 2009). Further animal studies have
shown that the glucocorticoid and adrenergic systems, the
two main stress activated pathways in the brain, act in
concert to enhance memory formation by acting within
the amygdala, hippocampus and prefrontal cortex (PFC)
(van Stegeren et al., 2009).
Given the important role of GR in stress reactions and the
anxiogenic properties of SP, surprisingly little is known of how
activation of GR might influence TAC1 expression in the
amygdala or how these interactions might be affected by
polymorphic variation. In the current study, we demonstrate
that activated GR can up-regulate the activity of the human
TAC1 promoter in primary amygdala neurones and identify
the specific sequences involved. We also demonstrate intri-
guing effects of population specific polymorphisms in the
TAC1 promoter on its ability to respond to GR activation. Thepossible implications of our results on the complex under-
pinnings of stress and anxiety are discussed.
2. Materials and methods
2.1. Primary cell culture
Neonate rats were bred internally using wild-type Sprague
Dawley rat damsmaintained under standard light/dark cycles
and given ad libitum access to food and water as outlined in
theUKHomeOffice ‘‘Codeof practice for the housing and care
of animals used in scientific procedure’’ (1986). Amygdala
tissues were dissected from postnatal day 0—3 pups that were
humanely sacrificed by cervical dislocation according to UK
Home Office Schedule 1 guidelines. Tissues were treated with
0.05% trypsin EDTA (Invitrogen, UK) for 15 min at 37 8C.
Trypsin EDTA was replaced with soybean trypsin inhibitor
(Sigma, UK) for 5 min at 37 8C to stop the reaction. This
was then replaced with supplemented Neurobasal A (Invitro-
gen, UK) followed by mechanical dissociation. For transfec-
tion analysis, cells were then resuspended in culture media
[Neurobasal A, B27 (Invitrogen,UK), 1 glutamax (Invitrogen,
UK) andPen/strep (100 U/ml) (Invitrogen,UK)] andplatedout
at a density of 80,000 viable cells/cm2 on poly-L-lysine
(20 mg/ml) (Sigma, UK) pre-treated plates following cell
counting for viable cells using TC10TM automated cell counter
(Biorad) with trypan blue. Cells were incubated at 37 8C, 5%
CO2 for 7 days prior to transfection. For mRNA analysis cells
were treated in the sameway as above except that they were
plated out in six well plates to a density of 500,000 per well
and cultured for 5 days prior to treatment with 50 mM Dex for
16 h. RNA was extracted using RNeasy Plus mini kit (Qiagen)
and cDNA was synthesised using Applied Biosystems high
capacity reverse transcriptase (Life Technologies).
2.2. Quantitative RT-PCR
Quantitative RT-PCR to determine Tac1 mRNA expression
levels from cultured rat primary amygdala cells treated with
either Dex or vehicle was undertaken on derived cDNA using
rat qRT-PCR primers (Qiagen) as previously described (Shan-
ley et al., 2010, 2011) using a Roche Light Cycler 480 with
Roche SYBR green and normalised using rat TATA binding
protein (TBP) specific primers.
2.3. Construct production
All derivatives of pTAC1promG-luc that contains the human
TAC1 promoter and was previously described as pTAC1prom-
Luc (Shanley et al., 2010, 2011) were generated using site
directed mutagenesis (SDM) using QuickChange II site direc-
ted mutagenesis kit (Agilent Technologies, UK). mut2GR-
TAC1promG-luc was produced using SDM using the
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TAGAACGATG-30 and 50-CATCGTTCTATAACCATACGGTCCCTC-
TTCTAAATCAA-30 (mutated bases in bold see Fig. 2A and
B). TAC1promT-luc was produced by SDM using the following
oligonucleotide, SNP-SDM 50-GAAGCAAAAAACGTCCTTTT-
CAACCCCTGCTCCTG-30 and 50-CAGGAGCAGGGGTTGAAAAG-
GACGTTTTTTGCTTC-30 (T-allele in bold see Fig. 2A and D).
2.4. Transfections and treatments
All DNA constructs were quantified by spectrophotometery
(NanoDrop Technologies) and the quantities of plasmid used
for each transfection were adjusted according to the size of
each plasmid to ensure molar equivalence between experi-
ments. Firefly luciferase plasmids were co-transfected with
Renilla luciferase plasmid, (pGL4.74, Promega, UK), to nor-
malise signals between transfections using magnetic parti-
cles (Neuromag, Oz Bioscience, UK) as described in
manufacturer’s instructions. Primary neuronal cultures were
incubated for 24 h prior to agonist or vehicle treatment.
Concentrations used were based on previous literature; Dex-
amethasone (Dex, 50 mM) (Pinho et al., 2011; Poulain et al.,
2012; Roomi et al., 2013; Wang et al., 2012), Phorbol 12-
myristate 13-acetate (PMA, 160 nM) (Meguro-Horike et al.,
2011), forskolin (10 mM) (Szatmari et al., 2007) angiotensin II
(AngII, 100 nM) (Modgil et al., 2011). Treatments were dis-
solved in ethanol (Dex) or DMSO (AngII, forskolin and PMA)
and cells exposed for 16 h. Concentrations of DMSO and
ethanol were equivalent in study and vehicle control groups
and never exceeded 0.05% and 1%, respectively. Cells were
harvested and dual luciferase assays were performed as
described in manufacturer’s instructions using GloMax 96
Microplate Luminometer with dual injectors (Promega, UK).
2.5. Nuclear extracts
SH-SY5Y cells were grown in the presence of dexamethasone,
forskolin or vehicle (ethanol and DMSO, respectively) for 24 h
to a final confluence of approximately 80%. Nuclear extracts
were prepared by the method of Dignam et al. (1983) in the
presence of protease inhibitors (complete protease inhibitor
cocktail from Roche plus 1.0 mM PMSF) and protein phospha-
tase inhibitors (5 mM b-glycerophosphate and 100 mM acti-
vated Na3VO4).
2.6. Electrophoretic mobility shift assays (EMSAs)
Twenty femtomoles of double stranded DNA oligonucleo-
tides, which had been 30 end-labelled with biotin and HPLC
purified, were incubated with either 10 mg SH-SY5Y cell
nuclear extracts or 2.0 mM purified full length recombinant
human GRa (Thermo Scientific, Cramlington, UK) as pre-
viously described (Hay et al., 2005) except that EDTA was
replaced with 50 mM ZnSO4. The sequences of the oligonu-
cleotides used were: GRE-cons, 50-TAAGTTTATGGTTACAAAC-
TGTTCTTAAAACGAGG-30; 2GR, 50-TTGATTTAGAAGAGG-
GATGTTCTGGTTATAGAACGATG-30; 2GR-mut, 50-TTGATTTA-
GAAGAGGGACCGTATGGTTATAGAACGATG-30; SNP-G (SNPGR-G)
50-GAAGCAAAAAACGTCCTGTTCAACCCCTGCTCCTG-30; SNP-T
(SNPGR-T) 50-GAAGCAAAAAACGTCCTTTTCAACCCCTGCTCCTG-30;
and a random oligonucleotide containing no regulatory ele-ments (RO) 50-CGAGCACCCTTCACCCTCCAGGCTTAACGG-30.
The 2GR and SNPGR based oligonucleotides represent human
TAC1 promoter sequence. Competing unlabelled oligonucleo-
tides were of the same sequence as the corresponding biotin
labelled ones and were added 15 min prior to the addition of
labelled probe at 100 molar excess. Supershift analyses
were carried out by the inclusion of either 1 ml anti-GR
antiserum (Santa Cruz sc1002) or 1 ml pre-immune rabbit
serum as a control, and incubation on ice for 30 min prior to
the addition of labelled probe. The resulting DNA:protein
complexes were resolved on 6% nondenaturing polyacryla-
mide gels run in 0.5 TBE buffer, pH 8.3 (45 mM Tris-borate,
1 mM EDTA) and visualised using Pierce LightShift Chemilu-
minescent reagents (Thermo Scientific, Cramlington, UK)
according to themanufacturer’s protocol. The relative inten-
sities of the DNA:protein complexes were determined by
digital integration using a Vilber Loumat Fusion SL cooled
CCD sensor with care being taken to ensure that no pixel
saturation occurred. Autorads of EMSA gels were used for the
figures and the order of some lanes within a gel was altered to
aid clarity and facilitate comparisons.
2.7. Statistical analysis
Experimental data was derived from tissues recovered from
at least three different groups of animals (n  3) and each
group was analysed in triplicate. Statistical significance of
data sets were analysed using either 2 way ANOVA analysis
with post hoc Holm—Sidak test using SigmaPlot Build
11.0.0.75 or one and two tailed Student’s t-test using Graph-
Pad PRISM version 5.02 where appropriate.
3. Results
3.1. Treatment of primary amygdala neurones
with Dex in culture up-regulates the expression
of the endogenous Tac1 gene
In order to explore the effects of Dex on the expression of
TAC1 in amygdala, primary neonatal rat amygdala neurones
(n = 3) were cultured for 5 days before being exposed for 16 h
to vehicle or Dex. Total RNA was recovered from these cells
and qRT-PCR performed on derived cDNA using primers
against the rat Tac1 gene and normalised using primers
against TBP. Consistently increased levels of Tac1 mRNA of
between 25% and 40% were observed following treatment
with Dex (Fig. 1A).
3.2. The conserved human TAC1 promoter is
responsive to Dex in primary amygdala neurones
Because of the known role of TAC1 in anxiety related beha-
viour and the ability of the Tac1 gene to respond to both
stress (Ebner et al., 2004; Sergeyev et al., 2005) and Dex in
primary amygdala cell culture, we investigated whether the
human TAC1 promoter was responsive to Dex in primary
amygdala cells using pTAC1prom-Luc that will be subse-
quently referred to as pTAC1promG-luc to reflect the specific
genotype at the rs17169049 locus (discussed later). pTAC1-
promG-Luc was magnetofected into primary amygdala neu-
rones and one hour later, cultured in the presence of a vehicle
[(Figure_1)TD$FIG]
Figure 1 (A) QrtPCR analysis of endogenous Tac1 gene expression in primary rat amygdala cells treated for 16 h with Dex (n = 3;
*p < 0.05). (B) Relative luciferase gene expression driven by either the minimal promoter construct pGL4.23 or TAC1promG-luc
plasmids when transfected into primary amygdala neurones (n = 9). (C) Diagrammatic representation (not to scale) demonstrating the
linear relationships of the components of each of the different constructs used in the current study. Bent black arrows indicate the
transcriptional start site of the luciferase marker gene (Luc). (D) Relative luciferase activity of the constructs represented in C
following transfection into amygdala neurones in the presence of vehicle or Dex. In each case n > 3. n.s., not significant; *p < 0.05;
**p < 0.01.
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luc supported higher levels of luciferase gene expression than
the pGL4.23 reporter that contained a minimal TATA box
promoter. Significantly, and consistent with data above show-
ing that Dex induced expression of endogenous Tac1, pTAC1-
promG-luc expression was up-regulated in primary amygdala
neurones following 16 h of exposure to Dex (Fig. 1B; n = 4;
p < 0.01).
3.3. A 473 bp region at the 50 end of TAC1prom is
required for Dex induction
In order to determine the identity of the Dex response
element within the TAC1 promoter, pTAC1promG-luc was
subjected to a series of restriction endonuclease deletions
that successively removed regions of the TAC1prom region of
pTAC1promG-luc (Fig. 1C). These deletion constructs were
transfected into amygdala neurones and treated with Dex for
16 h and relative luciferase activities were determined. In
the absence of Dex, the removal of a region 473 bp from the
50 end of the TAC1 promoter region to produce pDZTAC1prom-
luc had no significant effect on basal luciferase expression
when compared to pTAC1promG-luc (Figs. 1C and 2A). Dele-
tion of a further 116 bp to produce pDBgTAC1prom-luc
(Figs. 1C and 2A) did, however, reduce basal luciferaseexpression (Fig. 1C; n = 4; p < 0.01) and deletion of the
entire TAC1 promoter leaving only the transcriptional start
site of the luciferase plasmid prevented expression such that
no significant difference between the minimal promoter
construct (pGL4.23) and pDNTAC1prom-luc was observed
(Fig. 1D; n = 3; p < 0.01). These data suggest that regulatory
elements required to support marker gene expression in
amygdala neurones are contained between 219 and 349 bp
50 of the TAC1 transcriptional start site (between the ZraI and
BglII restriction sites; see Figs. 1C,D and 2A). Interestingly,
none of the deletion constructs that lacked sequence distal
to the ZraI site were responsive to Dex (Figs. 1C,D and 2A).
Thus, the regulatory elements required for basal expression
in amygdala neurones and those required for the response to
Dex are not contained within the same region. Furthermore,
Dex response elements are contained within TAC1prom distal
to the ZraI restriction site that was termed the ZB sequence
(see Figs. 1C and 2A). In order to explore the sufficiency of
the ZB sequence for the TAC1prom response to Dex, the ZB
sequence was cloned into pGL4.23 that contains a minimal
TATA box promoter (pDNZTAC1G-luc) and transfected into
amygdala neurones. However, pDNZTAC1prom-luc failed to
support marker gene expression either in the presence or
absence of Dex (data not show). Based on our previous
evidence for enhancer-promoter specificity at the TAC1 locus
[(Figure_2)TD$FIG]
Figure 2 (A) Scale line diagram showing features described in the text including restriction sites, putative GR binding sites (filled
black boxes), the rs17169049 SNPand the TAC1 transcriptional start site (bent arrow). Numbering refers to the location of each feature
on chromosome 7 based on the Human Feb. 2009 (GRCh37/hg19) assembly. (B—D) Multiple genome alignments of sequences within the
TAC1 promoter that contain predicted GR binding sites (B; 2GR and C; SNPGR, binding matrices >0.75 match to Transfac GR consensii)
demonstrating alignment between 13 placental mammals. Broken black boxes represent the extent of predicted GR binding matrices
and solid black boxes represent matches to known GR core binding motifs. Numbers at the end of each sequence in brackets represent
the degree of match to known Transfac GR binding matrices for each species. Numbers with asterisks represent the predicted match of
non-homologous GR binding site matrices within the guinea pig and cat TAC1 promoters. yThe binding matrix match of the T-allele of
rs17169049 is reduced to 0.626. (C) Linear alignment of the human TAC1 promoter sequence around 2GR (broken black box) with the
more diverged rat and mouse sequences highlighting the presence of a recognisable GR binding site (Transfac GRQ6 consensus in bold
with core sequence highlighted with a solid black box). (B—D) Numbers above the alignments represent the genomic co-ordinates of
human sequence (GRCh37/hg19 assembly) and numbers in D in italic represents the position of SNP rs17169049(G/T; underlined in D).
Sequences labelled ‘‘Mutant’’ represent the sequence of oligonucleotide primers (changes underlined) used for site directed
mutagenesis to produce the mut2GR (B) and the SNPGR-T variant of rs17169049 (D) as well as for the EMSA studies. (E) Table
showing readout from RegSNP demonstrating predicted differences (Matrix Score) in GR binding between the G and T alleles of
rs17169049.
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construct containing the ZB sequence next to the smallest
region of TAC1prom known to support marker gene expres-
sion (pDBsTAC1prom-luc) to create pDZBTAC1prom-luc.
When transfected into cultured amygdala neurones,
pDZBTAC1prom-luc supported marker gene expression to a
level significantly greater than the minimal promoter con-
struct pGL4.23 (n = 3; p < 0.01) but did not respond to
treatment with Dex (Fig. 1C and D). These findings show
that the ZB sequence of the TAC1promoter, although required
for Dex stimulation of pTAC1promG-luc, is not sufficient and
requires the presence of other more proximal sequences.
3.4. Identification of a consensus GR site
required for Dex induction of pTAC1promG-luc
To further explore the existence of GR response elements
(GREs) in the ZB sequence, bioinformatic analysis using
Transfac was applied to identify possible GR binding sites.
Two GR binding sites were predicted in the human TAC1
promoter. The more proximal, that we called 2GR
(ch7:97360822—97360840), lay 448 bp upstream from the
TAC1 transcriptional start site (TSS) and was found to be
highly conserved in TAC1prom in species as divergent as
humans, tree shrews, fruit bats and dolphins (Fig. 2A and
B). Although 2GR has been highly conserved in the TAC1
promoter of all other mammalian species rodents demon-
strated high levels of divergence within this part of the TAC1
promoter. Despite this, closer analysis demonstrates that the
rodent Tac1 promoter has retained a recognisable, although
diverged, GR binding site (Fig. 2C). Site directed mutagenesis
(SDM) was used to disrupt the core GR binding consensus
sequence within the human 2GR to produce a mutant
sequence that, following examination of the GR position
weight matrices available through Transfac, was less likely
to bind GR (Fig. 2B). This construct, mut2GRTAC1promG-luc,
was transfected into primary amygdala neurones and cells
were treated for 16 h with vehicle control or Dex. Analysis of
luciferase gene expression revealed that mutGRTAC1promG
was not inducible following treatment with Dex (Fig. 3A;
n = 4; p < 0.05). This demonstrates that the highly conserved
consensus 2GR site is required for Dex induction of the TAC1
promoter.
3.5. Human recombinant Glucocorticoid
receptor protein can bind 2GR
We next reasoned that the GR protein binds directly to the
2GR regulatory element, and examined this possibility by
EMSA analysis using purified human recombinant GRa pro-
tein. Fig. 3B shows that DNA:protein complexes were formed
between purified GRa protein and 2GR oligonucleotide and
the pattern was very similar to that seen with consensus GRE
oligonucleotide (lanes 1 and 3) which represented the well
characterised active consensus GRE (GRE-cons) present in the
MMTV-LTR. Using densitometry of three different EMSA
experiments we saw that the 2GR-mut oligonucleotide,
representing the mutated form of the 2GR, and containing
the same mutation as that present in the luciferase reporter
plasmids, was bound by GRa with significantly less affinity
( p < 0.01) than the unmutated 2GR (Fig. 3B, lanes 1 and 2).GRa was completely blocked from binding 2GR by addition of
an excess of unlabelled GRE-cons oligonucleotide (Fig. 3B,
lane 4) whereas an unlabelled random oligonucleotide had no
effect on this interaction (Fig. 3B, lane 5) corroborating high
levels of specificity. Further confirmation of GR binding to
2GR was obtained by incubating 2GR and 2GR-mut oligonu-
cleotides in the presence of nuclear extracts derived from a
human neuroblastoma cell line, SH-SY5Y, cultured in the
presence or absence of Dex (Fig. 3C). Dex treatment sig-
nificantly increased binding of a single high molecular weight
complex to 2GR (Fig. 3C, lanes 1 and 2; p < 0.01; n = 7).
Densitometry analysis of three separate EMSA experiments
demonstrated that binding to 2GR-mut was significantly
reduced when compared to the un-mutated 2GR in the
presence or absence of Dex (Fig. 3D; n = 3; p < 0.01 and
p < 0.05, respectively). Addition of an excess of the unla-
belled GRE consensus oligonucleotide almost eliminated the
Dex inducible complex from the 2GRoligonucleotide (Fig. 3C,
lanes 6 and 7) whereas a random oligonucleotide had no
effect (Fig. 3C, lane 8). Finally, incubation of Dex treated SH-
SY5Y nuclear extract in the presence of serum raised against
the GR protein clearly disrupted the interaction of the Dex
inducible complex with 2GR (Fig. 3E, lanes 1 and 2).
3.6. pTAC1prom-luc also responds to Forskolin
We next investigated whether stimulation of different intra-
cellular pathways could induce the TAC1 promoter in primary
amygdala neurones. In order to explore the identity of other
interacting signal transduction pathways amygdala neurones
transfected with pTAC1promG-luc were treated with forsko-
lin (adenylate cyclase agonist), PMA (PKC agonist) or AngII
(MAPkinase agonist). However, no significant change in
expression of pTAC1promG-luc following treatment with
either PMA (Fig. 4A; n = 4; p > 0.05) or AngII (Fig. 4A;
n = 3; p > 0.05) was observed suggesting that neither PKC
nor MAPKinase signalling cascades are involved in regulating
TAC1prom activity in amygdala neurones. However, treat-
ment with forskolin increased the activity of pTAC1promG
twofold (Fig. 4A; n = 4; p < 0.01). This response was of
similar magnitude to that observed following induction with
Dex and the response was not altered by simultaneous expo-
sure to Dex and forskolin (Fig. 4B; p > 0.05).
3.7. 2GR is required for TAC1prom response to
Forskolin in amygdala neurones
To investigate the elements required for forskolin induced
pTAC1promG-luc expression we transfected amygdala neu-
rones with the same deletion constructs used for investigat-
ing the identity of the response elements required for Dex
induction (Fig. 1C), and treated them with forskolin. In a
manner consistent with the results previously obtained for
Dex, deletion of the first ZB sequence to produce pDZTAC1-
promG-luc or any of the subsequent deletion constructs,
removed the ability of TAC1prom to respond to forskolin
(Figs. 1D and 4C; p > 0.05). These data suggest that the
elements required for forskolin induction of pTAC1promG-
luc lie in the same region necessary for Dex induction.
Furthermore, when transfected into amygdala neurones,
mut2GRTAC1prom-G was not induced following treatment
[(Figure_3)TD$FIG]
Figure 3 (A) Relative luciferase gene expression driven by either the pTAC1promG-luc or mut2GRTAC1prom-Luc plasmids when
transfected into primary amygdala neurones treated with vehicle or Dex (n = 9). (B) EMSA analysis of purified recombinant human GRa
protein incubated with labelled oligonucleotide probes representing wild type 2GR (2GR); mutated 2GR (2GR-mut) or consensus MMTV-
LTR glucocorticoid response element (GRE-cons) and (above) 100 fold molar excess of unlabelled competing GRE-cons oligonucleotides
or random oligonucleotide (RO). (C) Lanes 1—6; EMSA analysis of labelled 2GR, 2GR-mut or GRE-cons oligonucleotides incubated with
nuclear extracts derived from SH-SY5Y cells treated with vehicle or Dex. Lanes 7 and 8; competitive gel shift assays carried out with
competing GRE-cons or RO. (D) Densometric analysis of high molecular weight DNA:protein complexes in lanes 1—4, significance:
*p < 0.05; **p < 0.01. (E) Lanes 1—6, nuclear extract from SH-SY5Y cells previously incubated in Dex and incubated with labelled probe
representing the 2GR, SNP-G or the GR binding consensus sequence (GRE-cons) after pre-incubation with rabbit pre-immune serum ()
or antibody (+). 2GR (Lanes 1 and 2), SNPGR-G (SNP-G; Lanes 3 and 4) and GRE-cons (Lane 5 and 6) were incubated with SH-SY5Y nuclear
extracts in the presence or absence of Anti-GR antibody that reduced GR binding to each of the probes. These EMSAs were exposed to
electric fields for an additional 30 min to facilitate resolution of high molecular weight DNA:protein complexes.
lucocorticoid receptor regulation of TAC1 in amygdala 49with forskolin (Fig. 4D; n = 5; p < 0.01). Thus, consistent with
the results obtained for Dex, the 2GR site is essential for
forskolin-induced expression of pTAC1promG-luc.
3.8. 2GR binds GR in the presence of forskolin
We explored whether binding of GR to 2GR could also be
stimulated by forskolin as PKA activation is known to influ-
ence GR binding (Gruol and Altschmied, 1993; Gruol et al.,
1986). EMSAs were carried out on nuclear extracts derived
from SH0SY5Y cells treated with vehicle or forskolin. Cell
extracts derived from cells exposed overnight to forskolincontained GR proteins with increased ability to bind 2GR (Fig.
4E(lanes 1 and 2) and F; n = 3; p < 0.01). While forskolin was
still capable of significantly inducing GR binding to 2GRmut
its ability to do so was significantly reduced when compared
to 2GR (Fig. 4E(lanes 1—4) and F; n = 3; p < 0.01).
3.9. Identification of a second polymorphic
consensus GR binding site within TAC1prom
In addition to 2GR, bioinformatic analysis of the Dex respon-
sive ZB sequence also predicted the presence of a second
consensus GR binding site 643 bp away from the TAC1 TSS
[(Figure_4)TD$FIG]
Figure 4 (A) Bar graph representing fold induction of relative luciferase expression following treatment of primary amygdala
neurones transfected with pTAC1promG-luc and treated with forskolin, PMA or angiotensin II. (B) Comparison of the fold induction in
relative luciferase levels induced from pTAC1promG-Luc in response to treatment with Dex, forskolin or treatment with Dex and
forskolin simultaneously. No significant difference was observed between treatments. n  3; p = 0.33. (C) Bar graph showing relative
luciferase activity in the presence of vehicle or forskolin in each of the constructs represented in Fig. 1D. **p < 0.01; n  3. (D) Bar
graph representing relative fold induction of the pTAC1promG-Luc and mut2GRTAC1promG-luc constructs by forskolin. (E) Lanes 1—6;
EMSA analysis of labelled 2GR, 2GR-mut or GRE-cons oligonucleotides incubated with nuclear extracts derived from SH-SY5Y cells
treated with vehicle or forskolin. Lanes 7 and 8; competitive gel shift assays carried out with competing GRE-cons or RO. (F)
Densometric analysis of high molecular weight DNA:protein complexes in lanes 1 to 4, significance: *p < 0.05; **p < 0.01. EMSAs are
representative of at least 3 independent experiments and the order of some lanes within a gel has been altered to facilitate
comparison.
50 C.W. Hay et al.which was termed SNPGR (Fig. 2A and D). In contrast to 2GR,
which was highly conserved in many different mammalian
species, SNPGR is only conserved in higher primates (Fig. 2D).
Interestingly, SNPGR contained a single nucleotide poly-
morphism (SNP; rs17169049; G-T) whose minor T-allele has
only been described in Chinese and Japanese populations
where 12% and 20% of these populations are heterozygous
respectively.3.10. The T-allele of rs17169049 within SNPGR
binds GR to a lesser extent than G allele
Using the RegSNP programme (viis.abdn.ac.uk/regsnp/
Home.aspx) we predicted that GR binding to the T-allele
of rs17169049 within SNPGR (SNPGR-T) would be reduced by
26.7% compared to the major G allele (SNPGR-G; Fig. 2D). In
order to explore this prediction we incubated purified GRa
[(Figure_5)TD$FIG]
Figure 5 (A) EMSA analysis of purified recombinant human GRa protein incubated with oligonucleotide probes representing the Tor G
alleles of the SNPGR regulatory element (SNP-G and SNP-T) or consensus GRE (GRE-cons). (B) Densometric analysis of high molecular
weight DNA:protein complexes in lanes 1 and 2 (n = 3; ** p < 0.01). (C) Relative luciferase gene expression driven by either the
pTAC1promG-luc or pTAC1promT-Luc plasmids when transfected into primary amygdala neurones treated with vehicle or Dex (n = 9).
(D) Bar graph representation of the fold induction in relative luciferase expression from the indicated luciferase reporter constructs
transfected into primary amygdala neurones in response to overnight treatment of primary amygdala neurones with Dex compared
with vehicle treated samples following magnetofection with SDM altered versions of pTAC1prom-Luc. In each case n > 3. **p < 0.01;
*p < 0.05. (E and F) Diagrammatic representations of the two different hypotheses presented in the discussion to explain the effects of
the T-allele of SNPGR on the activity of 2GR. (E) The sequestration hypothesis and (F) The repression hypothesis.
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52 C.W. Hay et al.protein in the presence of oligonucleotides corresponding to
both allelic variants of the SNPGR sequence and analysed
their interactions using EMSA (Fig. 5A). Intriguingly, denso-
metric analysis of the high molecular weight DNA:protein
complexes in 3 different EMSAs showed that binding of GRa to
the SNPGR-T was 37% less when compared with binding to
SNPGR-G (Fig. 5A(lanes 1 and 2) and B; n = 3; p < 0.01).
Excess unlabelled GRE-consensus oligonucleotide could com-
pletely disrupt GRa binding to SNPGR demonstrating the
specificity of the interaction whereas a random oligonucleo-
tide (RO) had no effect (Fig. 5A, lanes 4—6). In addition,
binding of GR to SNPGR-G was corroborated by incubation of
Dex treated SH-SY5Y nuclear extract in the presence of serum
raised against the GR protein which disrupted DNA:protein
complex formation (Fig. 3E, lanes 3 and 4).
3.11. The SNPGR-T allele of TAC1prom is more
responsive to Dex induction
To determine whether the different alleles of SNPGR play a
role in altering tissue responsiveness to Dex, site directed
mutagenesis of pTAC1promG-luc was used to produce pTAC1-
promT-luc that contained SNPGR-T. Exposure of amygdala
neurones transfected with pTAC1promT-luc to Dex for 16 h
led to a significant increase in luciferase activity compared to
vehicle treated neurones transfected with pTAC1promT-luc
(Fig. 5C; n = 5; p < 0.01). Despite no difference in luciferase
activity between the two alleles in the absence of Dex
(Fig. 5C; p > 0.05), TAC1promT-luc responded to Dex treat-
ment much more strongly than the major allele TAC1promG-
luc (Fig. 5C; n = 5; p < 0.05).
3.12. Both alleles of SNPGR are unresponsive to
Dex induction in the absence of 2GR
We examined the role of the SNPGR site in the TAC1prom
response to Dex by mutating the 2GR sites from both TAC1-
promG and TAC1promT. In both cases, neither the G or T
alleles of the TAC1promoter responded to Dex in the pre-
sence of themutated 2GR site (Fig. 5D). These results suggest
that, although both SNPGR alleles were able to bind GR to
varying degrees (Fig. 5A, lanes 1 and 2), these interactions
were insufficient to activate transcription of TAC1prom in the
absence of 2GR and in the presence of Dex.
4. Discussion
In the current study, we demonstrate that activation of GR is
able to increase Tac1 mRNA expression in cultured rat pri-
mary amygdala neurones. Using a combination of reporter
construct deletion analysis and gene magnetofection into
primary amygdala neurones, we show that a 723 bp fragment
of the TAC1 promoter is highly Dex inducible and that the
most distal 473 base pairs of this fragment are necessary for
this response. Further analysis using bioinformatics and com-
parative genomics predicted the presence of a highly con-
served GR binding site. This site was termed 2GR, and its
mutation prevented TAC1prom from responding to GR acti-
vation in primary amygdala neuronal cultures. EMSA analysis
with purified GR protein revealed an interaction between
2GR and the GR protein, which could be disrupted using anunlabelled consensus GR oligonucleotide. Finally the incuba-
tion of Dex-treated SH-SY5Y cell nuclear extracts with anti-
GR antibody greatly reduced the binding of the Dex induced
complex to 2GR. These separate lines of evidence corrobo-
rate the hypothesis that GR activation can modulate TAC1
gene expression in amygdala at the highly conserved 2GR
sequence.
In addition to glucocorticoids, the stress response involves
the production of epinephrine that binds and activates adre-
nergic receptors that influence gene expression via the PKA
pathway (Deyama et al., 2008). We demonstrated that TAC1-
prom activity was responsive to forskolin activation in pri-
mary amygdala neurones; a response that depended on the
2GR binding site. These observations support the hypothesis
that, in addition to Dex, binding of GR to 2GR can also be
modulated by PKA activation. Our observations are consis-
tent with previous reports that forskolin and cAMP analogues
such as 8-bromo-cAMP and dibutyryl-cAMP, increased gluco-
corticoid steroid binding to GR (Gruol and Altschmied, 1993;
Gruol et al., 1986; Oikarinen et al., 1984). Analysis of the
pathways controlling the expression of proenkephalin
(ProENK) and thyroid releasing hormone genes also identified
an interaction between glucocorticoid and PKA pathways
that, in the case of ProENK, did not involve CREB or AP-1
phosphorylation (Perez-Martinez et al., 1998; Won and Suh,
2000). Further studies demonstrated a functional interaction
between PKA pathways and glucocorticoids within the amyg-
dala in vivo (Roozendaal et al., 2002). These observations
suggest that the GR influence on TAC1prom activity may be
modified by parallel induction through the PKA and gluco-
corticoid pathways providing a combinatorial mechanism
through which corticosteroids and epinephrine may alter
the expression of the TAC1 gene in amygdala neurones. It
has not escaped our notice that the discovery of a highly
conserved sequence within the human TAC1 promoter that
responds to GR activation provides a critical ‘‘link’’ in the
‘‘chain’’ of events that links the stress response (through GR
activation) to anxiety (through up-regulation of TAC1 expres-
sion in the amygdala). If a way could be found to manipulate
this interaction in the future it may be possible to modulate
the mechanistic link between stress and anxiety and reduce
the worst symptoms of conditions such as post-traumatic
stress disorder.
It is also important to consider that, in addition to SP, TAC1
also encodes another neuropeptide called neurokinin-A
(NKA) which, because it is encoded by the same mRNA, is
also likely to be expressed in the amygdala and to be affected
by GR modulation of the TAC1 promoter. This is interesting as
antagonist blockade of the NKA receptor; NK2, using sare-
dutant (SR48968) has demonstrated anti-depressant-like
activity in several rodent models (Louis et al., 2008) and
provides a second possible mechanistic link between GR
activation and mood modulation through expression of TAC1.
This model is, however, further complicated by the pre-
sence of a second putative GR binding site in humans 193 base
pairs distal of 2GR. This second GR site is less conserved than
2GR and contains a polymorphism (rs17169049-G/T) that has
so far only been observed in Japanese and Chinese popula-
tions. Using the RegSNP on-line algorithm we predicted that
the less frequent T-allele of SNPGR would have 26.7% less
affinity for GR than the more common G-allele. These pre-
dictions were confirmed using EMSA studies which showed
Glucocorticoid receptor regulation of TAC1 in amygdala 53that the T-allele reduced binding of GR in the form of purified
protein to SNPGR by 37%. Based on this observation we
predicted that the TAC1promoter containing the G-allele
of SNPGR would demonstrate greater sensitivity to Dex by
working in tandem with 2GR. However, we were surprised to
find that the T-allele of TAC1prom was twice as strongly
induced as was the G-allele. Furthermore, mutation of
2GR within the TAC1prom reporter showed that, despite
being able to bind GR, neither SNPGR-G nor SNPGR-T is able
to contribute to the response of TAC1prom to Dex. Clues as to
how this polymorphism affects TAC1 promoter GR response
come from experiments that have used ‘‘decoy’’ oligonucleo-
tides to manipulate the activity of promoter elements in cells
(Obata et al., 2011). Using this approach activated transcrip-
tion factors are sequestered away from promoter regions
following transfection of ‘‘decoy’’ oligonucleotides. A num-
ber of studies have suggested that variation within repetitive
elements may affect the activity of promoters by sequester-
ing activated transcription factors (Lee and Maheshri, 2012;
Liu et al., 2007). Based on these studies, we hypothesise that
SNPGR may act as a ‘‘decoy’’ site for activated transcription
factors such as GR. Thus, SNPGR-Gmay sequester GR proteins
from the functional 2GR site thereby reducing the GR-
mediated induction of TAC1prom. In contrast SNPGR-T is less
able to sequester GR thus increasing the likelihood of GR
binding to 2GR (Fig. 5E). A competing, though less elegant,
hypothesis is that the SNPGR-G allele binds a repressor
protein that reduces the affinity for GR binding at 2GR to
activate RNApolII whereas the T-allele lacks affinity for said
repressor (Fig. 5F).
Clearly, more work is required to identify the precise
mechanisms that allow the SNPGR-G allele to reduce the
ability of 2GR to respond to GR activation. It will also be of
intense interest to discover how the activation of both GR and
MR by corticosterone influences the activity of the TAC1
promoter. Moreover, the phenomenon of allele specific
repression of GR activation outlined here is significant for
our understanding of disease mechanisms; suggesting that
SNPs within demonstrably inactive parts of the genome can
significantly affect the activity of functional elements.
Anxiety disorders have been diagnosed in all human socie-
ties, and display cultural particularities in symptoms and
prevalence. Although the observed differences in rates
among the various disorders across cultural groups reflect
dissimilar prevalence, variability in measurement equiva-
lence, diagnostic criteria and precision are also factors
(Lewis-Fernandez et al., 2010) and preclude simple attempts
to determine a direct correlation between the SNPGR geno-
type and general anxiety levels. However, now that the
biological implications of this SNP have been revealed in this
report, it is vital that research groups with the necessary
resources e.g. DNA libraries from subjects of different ethni-
cities with accurate psychological assessments, explore pos-
sible phenotypic consequences. A tantalising suggestion of
the potential importance of this SNP comes from examination
of the haplotype frequencies in the publically available
dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/). The
observed haplotype frequencies for G/G homozygotes and G/
T heterozygotes in the Japanese and Han Chinese groups
adhere to Hardy-Weinberg proportions, however, no T/T
homozygote was observed. Intriguingly, the T allele fre-
quency and sample number (n = 170) in the Japanese studywere both sufficiently high that the absence of T/T homo-
zygotes was of statistical significance ( p < 0.05).
It is likely that the ability of TAC1prom to respond to GR
activation arose early in mammalian evolution to allow the
up-regulation of TAC1 expression in the amygdala in response
to stressful stimuli such as predation, disease, famine or
drought. However, the more recent evolution of SNPGR
may have allowed a tempering of the GR response of TAC1-
prom in higher primates possibly serving to reduce the effects
of stress hormones on the expression of TAC1 and reducing
levels of anxiety in these animals. Moreover, the accumula-
tion of SNPGR-T in modern Japanese and Chinese populations
is of particular interest in light of the disturbing rates of
suicide reported by the World Health Organisation in this part
of the world (Kohyama, 2011). Expanded population studies
should cast light on the possible role of the SNP, and have the
potential to facilitate development of personalised thera-
peutic strategies.
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